Psyence Biomedical attributes higher R&D costs to Phase IIb trial progress
PBM•Psyence Biomedical reported a net loss of $1.94 million for the six months ended September 30, 2026, and attributed $890,254 in research spending to progress in its Australian Phase IIb study. Cash, including restricted cash, was $21.14 million.
1. Six-month results
Psyence Biomedical management commentary reported a narrower net loss of $1.94 million for the six months ended September 30, 2026. Research spending was $890,254, which management attributed to progress in the Australian Phase IIb study, including patient recruitment and dosing.
2. Cash and expenses
Insurance recoveries contributed $424,695 to other income, while interest income rose to $362,187 as invested cash balances increased. Lower legal spending reflected fewer corporate transactions, and general and administrative expenses fell to $320,000 following cost discipline. Cash, including restricted cash, reached $21.14 million, supported by $16.78 million in net common-share issuance proceeds under the ELOC.




